- Identify and review current approaches to assessing economic impact of NM.
    - Accumulate data available between public and private sector inputs
    - Redefine the 'size' component of NT to Nanomedicine
  - What are their limitations?
    - Real market is hidden b/c companies do not specifically identify product or pipeline as "nanomedicine product"
    - Difficulties in defining downstream components of economic impact
    - Defining the instersection of nano- and bio- centric Medicine
  - Are they broadly applicable?
    -
  - Are there sufficient data available?
    - Depends on where on draws the lines for the definition of 'nano' medicine
    - Sentiment that there is data available, but it is difficult to categorize b/c SME/industry may not consider/want to consider their product as 'nanotechnology'
- What is not currently being captured by metrics that should be?
  - Spillover effects beyond spending input/outputs
  - Proper assignment of regional "economic multipliers"
  - The *potential* for advanced diagnostics for longer life through earlier detection
  - Recalcitrance of adoption of nanomedicine into standard of care and coverage by insuring agencies
  - Bottlenecks to development and implementation
  - The future of the health system
    - Changing of pharmaceutical R/D/implementation paradigm
    - The "IF" a reimbursement agency will cover a given therapy/diagnostic
- What is a reasonable objective to set for the economic assessment of the impact of NT in each sector in 3-5 years?
  - Needs to be done to support further government support of nascent technology
  - Re-categorization of current Tx + Dx on market to define nano-component of the market
    - Get government to refine standard industrial code to
  - Develop scenarios on novel treatments, advanced diagnostics, of likely impacts: use as predictive econ models
    - Life expectancy
    - Reduced hospital stay